Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Rapid genotypic antibiotic susceptibility test using CRISPR-Cas12a for urinary tract infection

Author affiliations

Abstract

The current clinical protocol to conduct a bacterial antibiotic susceptibility test (AST) requires at least 18 hours, and cannot be accomplished during a single visit for patients. Here, a new method based on the technique of CRISPR-Cas12a is utilized to accomplish a bacterial genotypic AST within one hour with good accuracy. Two amplification approaches are employed and compared: (1) enriching the bacterial concentration by culturing in growth media; and (2) amplifying target DNA from raw samples by recombinase polymerase amplification (RPA). The results show that CRISPR combined with RPA can rapidly and accurately provide a bacterial genotypic AST of urine samples with urinary tract infections for precise antibiotic treatment. As such, this technology could open a new class of rapid bacterial genotypic AST for various infectious diseases.

Graphical abstract: Rapid genotypic antibiotic susceptibility test using CRISPR-Cas12a for urinary tract infection

Back to tab navigation

Supplementary files

Article information


Submitted
11 May 2020
Accepted
07 Jun 2020
First published
09 Jun 2020

Analyst, 2020, Advance Article
Article type
Paper

Rapid genotypic antibiotic susceptibility test using CRISPR-Cas12a for urinary tract infection

J. Chen, F. Jiang, C. Huang and L. Lin, Analyst, 2020, Advance Article , DOI: 10.1039/D0AN00947D

Social activity

Search articles by author

Spotlight

Advertisements